You have full text access to this OnlineOpen article

Cancer

Cover image for Cancer

1 June 2009

Volume 115, Issue 11

Pages 2377–2593

  1. News

    1. Top of page
    2. News
    3. Commentary
    4. Editorial
    5. Review Article
    6. Original Articles
    1. You have full text access to this OnlineOpen article
      CancerScope (pages 2377–2379)

      Carrie Printz

      Article first published online: 19 MAY 2009 | DOI: 10.1002/cncr.24276

  2. Commentary

    1. Top of page
    2. News
    3. Commentary
    4. Editorial
    5. Review Article
    6. Original Articles
    1. You have full text access to this OnlineOpen article
      Chloroquine in glioblastoma—New horizons for an old drug (pages 2380–2383)

      Anusheel Munshi

      Article first published online: 26 MAR 2009 | DOI: 10.1002/cncr.24288

      Interesting clinical data have emerged about clinical experience with chloroquine as adjuvant therapy for patients with glioblastoma multiforme (GBM). Chloroquine has the potential of opening new frontiers in the treatment of glial neoplasms and should be tested in large clinical trials.

  3. Editorial

    1. Top of page
    2. News
    3. Commentary
    4. Editorial
    5. Review Article
    6. Original Articles
    1. You have full text access to this OnlineOpen article
      Lymph node ratio in melanoma : A marker of variation in surgical quality? (pages 2384–2387)

      Andrew J. Spillane, Julie Winstanley and John F. Thompson

      Article first published online: 20 MAR 2009 | DOI: 10.1002/cncr.24295

      The N ratio is increasingly promoted as a better indicator of prognosis than the American Joint Committee on Cancer's N stage in a number of diseases including melanoma. The most likely explanation for these findings is variation of surgical quality that is able to be corrected by applying rigorous quality standards to complete lymph node dissections.

  4. Review Article

    1. Top of page
    2. News
    3. Commentary
    4. Editorial
    5. Review Article
    6. Original Articles
    1. You have full text access to this OnlineOpen article
      Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer (pages 2388–2399)

      Lockwood G. Taylor, Steven E. Canfield and Xianglin L. Du

      Article first published online: 27 APR 2009 | DOI: 10.1002/cncr.24283

      This systematic review and quantitative assessment of the literature on the skeletal and cardiac side effects associated with androgen-deprivation therapy (ADT) in men with prostate cancer indicated that ADT therapy is associated with an increased risk of skeletal fracture, incident diabetes, and cardiovascular-related mortality, although the absolute risk of these events is low. Preventive measures against these adverse effects as well as careful assessment of patient's baseline health status should be considered.

  5. Original Articles

    1. Top of page
    2. News
    3. Commentary
    4. Editorial
    5. Review Article
    6. Original Articles
    1. Disease Site

      Breast Disease
      You have full text access to this OnlineOpen article
      Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort (pages 2400–2409)

      Jennifer M. Giltnane, Christopher B. Moeder, Robert L. Camp and David L. Rimm

      Article first published online: 27 MAR 2009 | DOI: 10.1002/cncr.24277

      Automated fluorescence-based quantitative analysis of breast cancer tissue microarrays allows for multiplexing and clustering of protein expression data. Analysis of the 4 ErbB family proteins along with estrogen and progesterone receptor allows definition of a subset of HER-2–positive cases with worse outcome.

    2. Gastrointestinal Disease
      You have full text access to this OnlineOpen article
      A novel hypothesis on the sensitivity of the fecal occult blood test : Results of a joint analysis of 3 randomized controlled trials (pages 2410–2419)

      Iris Lansdorp-Vogelaar, Marjolein van Ballegooijen, Rob Boer, Ann Zauber and J. Dik F. Habbema

      Article first published online: 13 MAR 2009 | DOI: 10.1002/cncr.24256

      We tested 3 hypotheses for fecal occult blood test sensitivity: sensitivity is the same for all preclinical colorectal cancer stages, sensitivity increases with each stage, and the novel hypothesis that sensitivity is higher for the stage in which the cancer would have been diagnosed in the absence of screening than for earlier stages. The hypothesis with a higher sensitivity in the stage of clinical diagnosis gave the best fit to results of the randomized controlled trials of Minnesota, Nottingham, and Funen.

    3. You have full text access to this OnlineOpen article
      Benefit of postoperative adjuvant therapy for pancreatic cancer : A population-based analysis (pages 2420–2429)

      Kimberly A. Vanderveen, Steven L. Chen, Daixin Yin, Rosemary D. Cress and Richard J. Bold

      Article first published online: 19 MAR 2009 | DOI: 10.1002/cncr.24269

      Analysis of the California Cancer Registry (N = 3196 patients; 1994-2002) demonstrated that adjuvant therapy resulted in a modest improvement in overall survival after surgical resection of pancreatic cancer in selected patients with poor prognostic indicators (ie, lymph node positivity, high histologic grade). To identify effective systemic therapy for this deadly cancer, future clinical trials of adjuvant therapy should focus on these groups of patients.

    4. You have full text access to this OnlineOpen article
      Genetic polymorphism in chemokine CCL22 and susceptibility to Helicobacter pylori infection-related gastric carcinoma (pages 2430–2437)

      Guanghai Wang, Dianke Yu, Wen Tan, Dan Zhao, Chen Wu and Dongxin Lin

      Article first published online: 19 MAR 2009 | DOI: 10.1002/cncr.24255

      In this study, genetic polymorphism in chemokine (C-C motif) ligand 22 (CCL22), a chemokine that plays an important role in suppressing immune responses against microbial infections and tumors, was associated with increased gastric cancer risk both alone and in combination with Helicobacter pylori infection.

    5. Genitourinary Disease
      You have full text access to this OnlineOpen article
      A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer (pages 2438–2446)

      Robert J. Amato, Jaroslaw Jac, Sarah Giessinger, Somyata Saxena and James P. Willis

      Article first published online: 20 MAR 2009 | DOI: 10.1002/cncr.24280

      This phase 2 study assessed the activity of a 10-mg daily oral regimen of the mammalian target of rapamycin (mTOR) inhibitor everolimus in patients with metastatic renal cell cancer who had received no more than 1 prior treatment for their disease. The findings of a progression–free survival of 11.2 months and overall survival of 22.1 months encourage further investigation of daily everolimus in the treatment of both treatment-naïve patients and those with disease recurrence after treatment with cytokines or inhibitors of vascular endothelial growth factor receptor signaling.

    6. You have full text access to this OnlineOpen article
      Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base : Impact of Hospital Case Volume, Hospital Size, and Geographic Location on 40,000 Patients (pages 2447–2452)

      Robert E. Mitchell, Byron T. Lee, Michael S. Cookson, Daniel A. Barocas, S. Duke Herrell, Peter E. Clark, Joseph A. Smith and Sam S. Chang

      Article first published online: 23 MAR 2009 | DOI: 10.1002/cncr.24292

      Data from academic medical centers across the nation reveal that increasing hospital case volume has a positive impact on immediate surgical outcomes after radical nephrectomy. Length of stay, intensive care unit admission rates, and complication rates decrease as hospital case volume increases.

    7. Gynecologic Oncology
      You have full text access to this OnlineOpen article
      Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel (pages 2453–2463)

      Dan Su, Stephanie M. Smith, Mario Preti, Peter Schwartz, Thomas J. Rutherford, Guido Menato, Saverio Danese, Shenglin Ma, Herbert Yu and Dionyssios Katsaros

      Article first published online: 25 MAR 2009 | DOI: 10.1002/cncr.24282

      In this study, patients with ovarian cancer who received platinum plus paclitaxel had unfavorable survival if they high levels of tumor stathmin expression; however, that association was not observed in patients who received platinum without paclitaxel. These results support the notion that stathmin, a microtubule-interacting protein, may interfere with paclitaxel treatment, affecting patient survival.

    8. Head and Neck Disease
      You have full text access to this OnlineOpen article
      Postoperative reduced dose of cisplatin concomitant with radiation therapy in high- risk head and neck squamous cell carcinoma (pages 2464–2471)

      Giovanni Franchin, Emilio Minatel, Doriano Politi, Carlo Gobitti, Renato Talamini, Emanuela Vaccher, Maria Gabriella Savignano, Marco Trovo, Sandro Sulfaro and Luigi Barzan

      Article first published online: 11 MAR 2009 | DOI: 10.1002/cncr.24252

      A total of 75 mg/m2 of cisplatin concomitant with radiotherapy was an effective treatment in high risk, surgically treated, head and neck cancer patients. However, the toxicity rate remained relatively high, with only 48% of the patients receiving the planned chemotherapy cycles.

    9. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      Treating octogenarian and nonagenarian acute myeloid leukemia patients—Predictive prognostic models (pages 2472–2481)

      Antoine J. Harb, Wei Tan, Gregory E. Wilding, LaurieAnn Ford, Sheila N. J. Sait, AnneMarie W. Block, Maurice Barcos, Paul K. Wallace, Eunice S. Wang and Meir Wetzler

      Article first published online: 25 MAR 2009 | DOI: 10.1002/cncr.24285

      Treating octogenarian and nonagenarian patients who have acute myeloid leukemia (AML) with intensive chemotherapy is controversial. In this study, the authors performed a retrospective analysis to assist in treatment decisions for octogenarian and nonagenarian patients with AML.

    10. You have full text access to this OnlineOpen article
      Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy (pages 2482–2490)

      Alfonso Quintás-Cardama, Hagop Kantarjian, Farhad Ravandi, Susan O'Brien, Deborah Thomas, Gabriela Vidal-Senmache, William Wierda, Steven Kornblau and Jorge Cortes

      Article first published online: 11 MAR 2009 | DOI: 10.1002/cncr.24257

      The most frequent nonhematologic side effects associated with dasatinib therapy in patients with chronic myeloid leukemia are gastrointestinal, rash, and fluid retention syndromes. However, bleeding has been observed in some patients who are treated with dasatinib. In the current study, the authors investigated the incidence, severity, management, and outcome of bleeding episodes associated with dasatinib therapy.

    11. Hepatobiliary Disease
      You have full text access to this OnlineOpen article
      Real-time identification of liver cancers by using indocyanine green fluorescent imaging (pages 2491–2504)

      Takeaki Ishizawa, Noriyoshi Fukushima, Junji Shibahara, Koichi Masuda, Sumihito Tamura, Taku Aoki, Kiyoshi Hasegawa, Yoshifumi Beck, Masashi Fukayama and Norihiro Kokudo

      Article first published online: 26 MAR 2009 | DOI: 10.1002/cncr.24291

      This study demonstrated novel fluorescent imaging techniques using preoperative intravenous injection of indocyanine green, which enabled the highly sensitive identification of small and grossly unidentifiable liver cancers in real time, enhancing the accuracy of liver resection and operative staging.

    12. Melanoma
      You have full text access to this OnlineOpen article
      Lymph node ratio predicts disease-specific survival in melanoma patients (pages 2505–2513)

      Yan Xing, Brian D. Badgwell, Merrick I. Ross, Jeffrey E. Gershenwald, Jeffrey E. Lee, Paul F. Mansfield, Anthony Lucci and Janice N. Cormier

      Article first published online: 23 MAR 2009 | DOI: 10.1002/cncr.24290

      Various measures associated with lymph node (LN) dissection were examined to identify threshold values associated with disease-specific survival in patients with melanoma. LN ratio was the best indicator of the extent of LN dissection, and a total of 15, 8, and 6 LNs removed per positive lymph node in the neck, axillary, and inguinal region resulted in the greatest differences in DSS.

    13. Sarcoma
      You have full text access to this OnlineOpen article
      Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma (pages 2514–2522)

      David M. Loeb, Elizabeth Garrett-Mayer, Robert F. Hobbs, Andrew R. Prideaux, George Sgouros, Ori Shokek, Moody D. Wharam Jr, Tammy Scott and Cindy L. Schwartz

      Article first published online: 31 MAR 2009 | DOI: 10.1002/cncr.24286

      In the current study, samarium-153 ethylenediaminetetramethylene phosphonic acid was safely administered to heavily pretreated patients with high-risk osteosarcoma in a dose that allowed for reliable hematopoietic recovery within 6 weeks. A significant fraction of patients experienced temporary disease stabilization.

    14. Skin
      You have full text access to this OnlineOpen article
      Actinic keratoses : Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial (pages 2523–2530)

      Vincent D. Criscione, Martin A. Weinstock, Mark F. Naylor, Claudia Luque, Melody J. Eide, Stephen F. Bingham and for the Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group

      Article first published online: 20 APR 2009 | DOI: 10.1002/cncr.24284

      In this study, the authors used prospectively collected data from a high-risk population with up to 6 years of follow-up to quantify the risk of progression of actinic keratoses (AKs) to cancer. The findings suggest that AKs may play a larger role in the overall burden of keratinocyte carcinomas than previously appreciated.

    15. Discipline

      Diagnostic Imaging
      You have full text access to this OnlineOpen article
      18F-fluorodeoxyglucose and 11C-acetate positron emission tomography are useful modalities for diagnosing the histologic type of thymoma (pages 2531–2538)

      Hidekatsu Shibata, Hiroaki Nomori, Kimiichi Uno, Kazuya Sakaguchi, Rumi Nakashima, Kenichi Iyama, Katsumi Tomiyoshi, Masahiro Kaji, Tomoyuki Goya, Takashi Suzuki and Hirotoshi Horio

      Article first published online: 26 MAR 2009 | DOI: 10.1002/cncr.24278

      Both 18F-fluorodeoxyglucose (FDG)-and 11C-Acetate (AC) positron emission tomography cannot predict invasiveness of thymomas. Thymomas with FDG-standard uptake value (SUV) <6.3 and AC-SUV ≥5.7 are almost certainly types A/AB.

    16. Disparities Research
      You have full text access to this OnlineOpen article
      Mapping cancer mortality-to-incidence ratios to illustrate racial and sex disparities in a high-risk population (pages 2539–2552)

      James R. Hébert, Virginie G. Daguise, Deborah M. Hurley, Rebecca C. Wilkerson, Catishia M. Mosley, Swann A. Adams, Robin Puett, James B. Burch, Susan E. Steck and Susan W. Bolick-Aldrich

      Article first published online: 18 MAR 2009 | DOI: 10.1002/cncr.24270

      Mortality-to-incidence ratios (MIRs) can be computed from readily available sources to identify population groups that experience excess cancer mortality. Mapping MIRs enables planners and researchers to pinpoint places that require extra attention to reduce and eventually eliminate cancer-related health disparities.

    17. You have full text access to this OnlineOpen article
      Racial differences in medical mistrust among men diagnosed with prostate cancer (pages 2553–2561)

      Chanita Hughes Halbert, Benita Weathers, Ernestine Delmoor, Brandon Mahler, James Coyne, Hayley S. Thompson, Thomas Ten Have, David Vaughn, S. Bruce Malkowicz and David Lee

      Article first published online: 18 MAR 2009 | DOI: 10.1002/cncr.24249

      The objective of this study was to identify sociodemographic, clinical, and cultural determinants of medical mistrust among men diagnosed with prostate cancer. The results suggested that efforts to enhance trust among men who are diagnosed with prostate cancer should target African-American men, men with fewer socioeconomic resources, and men with lower perceptions of interdependence.

    18. Pediatric Oncology
      You have full text access to this OnlineOpen article
      Abnormal timing of menarche in survivors of central nervous system tumors : A Report From the Childhood Cancer Survivor Study (pages 2562–2570)

      Gregory T. Armstrong, John A. Whitton, Amar Gajjar, Larry E. Kun, Eric J. Chow, Marilyn Stovall, Wendy Leisenring, Leslie L. Robison and Charles A. Sklar

      Article first published online: 23 MAR 2009 | DOI: 10.1002/cncr.24294

      Survivors of childhood central nervous system tumors are at significant risk of both early and late onset of menarche associated with hypothalamic radiotherapy exposure and age at treatment.

    19. Symptom Control and Palliative Care
      You have full text access to this OnlineOpen article
      Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain : A long-term, open-label safety study (pages 2571–2579)

      Sharon M. Weinstein, John Messina and Fang Xie

      Article first published online: 16 APR 2009 | DOI: 10.1002/cncr.24279

      This study followed an opioid-tolerant patient population with chronic cancer pain for ≥12 months to evaluate a medication indicated for the treatment of breakthrough pain. The results demonstrated that fentanyl buccal tablets were generally well tolerated and had a favorable safety profile.

    20. Translational Research
      You have full text access to this OnlineOpen article
      Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer (pages 2580–2593)

      Shotaro Iwakiri, Nobuya Mino, Tsuyoshi Takahashi, Makoto Sonobe, Shinjiro Nagai, Kenichi Okubo, Hiromi Wada, Hiroshi Date and Ryo Miyahara

      Article first published online: 23 MAR 2009 | DOI: 10.1002/cncr.24281

      In pathological stage I nonsmall cell lung cancer, CXCR7 expression values in patients with postoperative metastatic recurrence are significantly higher than in those without recurrences. The 5-year disease-free survival rate of high CXCR7-expressing patients is significantly lower than that of low CXCR7-expressing patients.

SEARCH

SEARCH BY CITATION